Sociedad Americana de Hirudoterapia

Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update

Review published in Current neurology and neuroscience reports (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosFarmacología salivalLi M et al. · Current neurology and neuroscience reports, 2025

Abstract

PURPOSE OF REVIEW: Antithrombotic-associated intracerebral hemorrhage (ICH) is associated with high rates of morbidity and mortality. Rapid and effective antithrombotic reversal is critical for mitigating risk of hemorrhage expansion and neurological deterioration. This review provides an overview of the most recent advances in emergency antithrombotic reversal in ICH. RECENT FINDINGS: Rapid coagulopathy reversal within the first 60-90 min of hospital presentation may limit massive ICH expansion and improve outcomes. Current data suggests reversal of vitamin K antagonists with intravenous vitamin K and 4-factor prothrombin complex concentrates (4f-PCC), reversal of dabigatran with idarucizumab, and reversal or direct oral factor Xa inhibitors with either 4f-PCC or andexanet-alfa. While platelet transfusion is not suggested for antiplatelet-associated ICH, DDAVP may be reasonable, and a new reversal agent is under development for ticagrelor. Rapid reversal of antithrombotic-associated coagulopathy in the context of ICH may prevent ICH expansion and improve neurological outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansCerebral HemorrhageFibrinolytic AgentsBlood Coagulation Factors

Resumen

Antithrombotic-associated intracerebral hemorrhage (ICH) is associated with high rates of morbidity and mortality.

Por qué esto importa para la hirudoterapia

This review provides an overview of recent advances in emergency antithrombotic reversal for intracerebral hemorrhage, highlighting the importance of rapid coagulopathy reversal within the first 60–90 minutes of presentation and discussing agents such as 4-factor prothrombin complex concentrate, intravenous vitamin K, idarucizumab, andexanet alfa, and DDAVP. The abstract makes no mention of leeches, hirudotherapy, hirudin, or the leech secretome, and the article addresses antithrombotic reversal entirely within conventional pharmacological contexts. Its relevance to the American Society of Hirudotherapy is therefore negligible, as it provides no information pertinent to leech-based therapies or leech-derived anticoagulants.

Citación

Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update

Li M et al. · Current neurology and neuroscience reports, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.